理工学院朱宝亭教授领衔的新药研发团队获深圳市“孔雀团队”资助

CUHK (SZ) Professor Zhu Selected as a Shenzhen Peacock Plan Team Leader

理工学院朱宝亭教授领衔的新药研发团队获深圳市“孔雀团队”资助

The list of the Shenzhen Peacock Plan Teams 2016 has been published recently. The Anti-breast Cancer New Drugs Research Team, headed by Professor Bao-Ting Zhu at the School of Science and Engineering, has been selected. This is a second team from the University that will receive a research grant totaling RMB30,000,000.

2016年深圳市海外高层次人才“孔雀团队”结果近日揭晓，我校理工学院朱宝亭教授领衔的“抗乳腺癌新药研发团队”榜上有名，这是我校第二个获“孔雀团队”资助的研发团队，获无偿研究经费资助三千万元。

The team plans to engage in the preclinical research and development of a series of new drugs for the treatment of the estrogen-dependent breast cancer, and this pioneering research project will include the design, chemical synthesis, pharmacologic efficacy testing, and toxicity assessment of the new drugs.

“抗乳腺癌新药研发团队”由朱宝亭教授领衔。研发团队旨在对雌激素依赖性乳腺癌进行新药设计、化学合成、药理毒理等临床前系列创新性的新药开发研究。

朱宝亭教授

细胞和分子药理学专家

港中大（深圳）理工学院副院长、教授

＂千人计划＂专家

Team leader Professor Bao-Ting Zhu is an expert on molecular and cellular studies of cellular events and drugs. He was selected into the National Thousand-Talents-Plan in 2012 and currently serves as Professor and Associate Dean of the School of Science and Engineering at CUHK (SZ). 

团队带头人朱宝亭教授是细胞和分子药理学专家，2012年入选国家“千人计划”（长期项目），现任港中大（深圳）理工学院副院长及教授。

Professor Zhu obtained his B.M. and M.S. degree from Fudan University Shanghai Medical College in 1985 and 1988, respectively. He obtained his PhD degree in pharmacology from University of Texas in 1992. In 1998, he assumed an independent faculty position as an Assistant Professor at the University of South Carolina. While working there, he received promotions to Tenured Full Professor in 2004, and endowed Distinguished Professor in 2005. A year later, he was appointed as the Director for the Department of Basic Pharmaceutical Sciences. In 2007, Prof. Zhu joined the University of Kansas School of Medicine to assume a prominent academic position as the endowed William W. Abercrombie Distinguished Professor in Cancer Research.

朱宝亭教授于1985年、1988年先后就读于复旦大学医学院并获得医学学士学位和药理学硕士学位，1992年获美国德州大学药理学博士学位，1998年受聘美国南卡罗来纳大学任助理教授，2004年晋升为药理学终身教授，2005年晋升为药理学冠名杰出教授，2006年任南卡罗来纳州药学院系主任，2007年任堪萨斯大学医学院任肿瘤研究终身冠名杰出教授，同时任药理学终身教授及堪萨斯大学癌症中心肿瘤生物学研究组带头人。

One of Prof. Zhu’s research interests centers around the better understanding of the biochemical, molecular, and cellular mechanisms underlying the pharmacological actions of steroid hormones and drugs. In recent years, Prof. Zhu has also developed a strong interest in studying the memory and cognitive functions of the brain, in an effort to better understand the molecular and chemical mechanisms underlying these vital neuronal functions. Professor Zhu has authored or co-authored over 130 publications with 7000 citations. Professor Zhu has been invited to edit or review papers for more than 30 international journals, including Cancer Res, Endocrinology, JPET and PNAS. He is also a reviewer of several research foundations, including NIH, NSF, SNSF, and The Research Grants Council of Hong Kong.

朱宝亭教授的研究领域涵盖基础分子药理学、肿瘤药理学及疾病分子机理学。主要研究重点是甾体激素受体拮抗剂的设计、合成和药理功能的研究，已在国际上以第一或通讯作者发表了近130余篇高质量学术论文，引用次数7000次。朱宝亭教授应邀担任Cancer Res、Endocrinology、JPET、PNAS等30余种国际专业杂志审稿者或编委，任美国国立卫生研究所（NIH）、美国国立自然科学基金（NSF）、瑞士国家科学基金会以及香港研究资助局等科研基金的评审委员。

图片及内容由港中大（深圳）科研处提供

英文翻译/ 李斌武（CPRO）

编辑排版/ 郑天晴（2016级经管学院学生）